| Vertex Pharmaceuticals, Inc. | (NQ: VRTX) |
|
USD
|
|
Official Closing Price
/ Updated: /
|
| View: | Quote | News | Research |
(VRTX) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 19, 2013
(Stock Blog Hub,
4/27/13)
Actelion Ltd. (ALIOF) reported first quarter 2013 earnings of $1.35 per American Depository Receipt (ADR), up 56.1% from the prior-year earnings of 87 cents per ADR. Earnings were well...(read more)
(Stock Blog Hub,
11/24/12)
Vertex Pharmaceuticals Inc. (VRTX) posted break-even (including stock-based compensation expense) results in the third quarter of 2012, well below the year-ago earnings...(read more)
(tickerspy.com,
5/7/12)
Stocks ended the day mixed following Friday's big sell-off. The market looked poised to continue the downward trend following the results of the French election, but stocks quickly regained their composure to trade pretty much...(read more)
Vertex Pharmaceuticals (VRTX) Company Overview
There is no analysis for VRTX yet. But you can go to Wikinvest to help create one!
What's in this VRTX analysis on Wikinvest...
- Company Overview
- Business and Financial Metrics
- Products
- Telaprevir (VX-950)[4]
- VX-222[4]
- Additional HCV Research Activities and Development Programs[4]
- Cystic Fibrosis[4]
- VX-770[4]
- VX-809[4]
- VX-509[4]
- VX-765[4]
- Acquisitions
- Trends and Forces
- Risk Factors
- An advancement in HCV treatment is desperately needed
- Competition is heating up
- Drop in HCV infections
- Competition
- References
